Login to Your Account



Washington Roundup

FDA Adds Bladder Cancer Warning to Actos Label

By Catherine Shaffer


Friday, June 17, 2011
The FDA has added a warning to the label for Actos (pioglitazone) stating that the use of the medication for more than one year may be associated with an increased risk of bladder cancer. The statement by the FDA followed a review of data from a five-year interim analysis of an ongoing epidemiological study.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription